Supplemental Figure 1

Western blots of JAK-STAT and MEK-ERK pathways after the treatment with JAK inhibitor ruxolitinib for 1, 2, and 3 days. MCPyV-negative (MCC 13 and MCC14/2) and MCPyV-positive cell lines (MKL-1) treated with 5 μM and 50 μM of ruxolitinib.